MeOmics' mission is to improve the diagnosis and treatment of mental health illnesses through combining unique neuronal cell assays and data-rich descriptors of individual patients including genomics.
This will allow preclinical screening, prior to expensive phase III drug trials, and will also enable clinical screening of patients leading to personalised mental healthcare, shortening the time and cost to better patient outcomes.
Having proved the technology in an academic setting, we are now seeking funding to progress the scale-up of the process and technology as an exciting and high-growth potential bio-tech start-up.